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Purpose: The need for cross-femoral bypass grafting (CFBG) is considered by some to be a major disadvantage of
endovascular aneurysm repair (EVAR) with the aortomonoiliac technique. To determine the durability of CFBG in this
setting, we examined data from 148 consecutive high-risk patients in a clinical trial of EVAR with a custom-made
aortomonoiliac endovascular stent graft.
Methods: All data were collected prospectively. After hospital discharge, patients were evaluated at 1, 3, and 6 months and
annually thereafter. All CFBG was constructed of expandable polytetrafluoroethylene.
Results: During follow-up averaging 23.6  16.2 months, nine CFBG complications developed in 8 patients (5.4%),
including disruption (n  2), infection (n  3), thrombosis (n  2), and pseudoaneurysm (n  3). Four patients with
CFBG complications died, of consequences of infection (n  2), intracranial hemorrhage during attempted CFBG
thrombolysis (n  1), and intracranial hemorrhage during anticoagulation (n  1). There were no amputations. At life
table analysis, freedom from CFBG complication was 96.3%  1.6% at 12 months, 94.1%  2.2% at 24, 36, and 48
months, and 86.2%  7.8% at 60 months. Overall survival for this high-risk patient group was 83.4%  3.1% at 12
months, 70.4%  4.1% at 24 months, 56.5%  5.3% at 36 months, and 44.8%  6.4% at 48 months.
Conclusion: CFBG is durable, with a low rate of complications in patients undergoing aortomonoiliac EVAR. Need for
CFBG should not discourage use of aortomonoiliac devices in patients with anatomy unfavorable for other EVAR
approaches. (J Vasc Surg 2003;38:753-7.)
Since initial reports of endovascular aneurysm repair
(EVAR),1,2 studies have reported low mortality and mor-
bidity at intermediate follow-up, with use of currently
available devices.3-5
Applicability of EVAR in this population is limited
mainly by patient anatomy. Previously, as many as 50% of
patients were excluded because of tortuosity, narrowing,
or, occlusion of the iliac arteries.6 Continuing develop-
ments in endovascular device design have enabled more
patients to undergo EVAR; however, iliac artery anatomy
sometimes precludes implantation of a bifurcated endovas-
cular graft. Some otherwise excluded patients may be eligi-
ble for EVAR with an aortomonoiliac stent graft along with
cross-femoral bypass grafting (CFBG) and contralateral
iliac artery occlusion.1,2,7
The need for CFBG is considered by some to be a
major disadvantage of the aortomonoiliac approach,8,9 de-
spite recent experience with CFBG that indicated more
encouraging outcome.10-12 However, most reports de-
scribe the results of CFBG in patients with occlusive disease
or after removal of infected aortic grafts in small numbers of
patients.
We evaluated the durability and complication rate of
CFBG in a high-risk patient population undergoing EVAR
with a monoiliac stent graft.
METHODS
Between 1996 and 2001, 148 patients underwent
EVAR with an aortomonoiliac stent graft at the University
of California, San Francisco and the San Francisco Veterans
Affairs Medical Center. Median patient age was 76 years
(range, 54-92 years), and median aortic diameter was 6.2
cm (range, 2.6-10.7 cm). All patients had an aortic aneu-
rysm, except one patient with a ruptured iliac aneurysm. In
this patient, aortic diameter was only 2.6 cm. The proce-
dure was successfully completed in all 148 patients.
Study patients were considered to be high risk because
of comorbid conditions (Table I). All patients had Ameri-
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Table I. Patient comorbid conditions
Characteristic
No. of
patients %
Ischemic heart disease 110 74
Congestive heart failure 40 27
Chronic obstructive
pulmonary disease
52 35
Hypertension 51 34
Creatinine 1.6 24 16
Multiple previous abdominal
operations or morbid
obesity
46 31
753
Table II. Perioperative (30-day) mortality
Cause of death
No. of patients
(% total)
Related
to
EVAR
Related
to
CFBG Comments
Cardiac arrest/MI 3 (2) No No Primary cause of death, cardiac event; all had known ischemic heart disease
Sepsis 1 (1) No Yes CFBG infection leading to sepsis
Unknown 1 (1) No No Patient did not recover from general anesthesia, and multiple organ failure
developed. Autopsy findings consistent with multiple emboli;
endovascular stent graft and CFBG patent at autopsy
EVAR, Endovascular aneurysm repair; CFBG, cross-femoral bypass grafting; MI, myocardial infarction.
Table III. Postoperative complications not involving complications of cross-femoral bypass graft
Complication No. %
Related to
endovascular
repair Comments
CVA 1 1 No Patient had lacunar infarct 3 days postoperatively
Secondary stent graft infection 1 1 No Spinal tuberculosis resulted in stent-graft infection and sepsis
Ischemic colon 2 1 Yes Both patients underwent distal colectomy in inferior mesenteric
artery distribution
Endoleak 11 7 Yes Seven patients had type I endoleak, 5 patients had type II (1
patient had both types)
Endovascular stent migration 2 1 Yes Both patients did well after proximal endovascular stent
extension (at 15 months and 4 years, respectively,
postoperatively)
CVA, Cerebrovascular accident, confirmed at imaging.
Table IV. Postoperative complications related to cross-femoral bypass graft
Complication
Postoperative day
at presentation Management Outcome Risk factors
Graft infection 468 Graft removal;
reconstruction with
cryopreserved femoral
vein
Replacement graft patent
at last follow-up
History of renal transplantation,
immunosuppression therapy
Graft infection* 36 Graft removal;
reconstruction with
greater saphenous vein
Death from necrotizing
fasciitis of decubitus
ulcer
Femoral artery pseudoaneurysm
requiring repair on postoperative
day 1
Groin infection 10 Wound exploration,
sartorius muscle flap;
cross-femoral bypass graft
well-incorporated and
patent at exploration
Death from multiorgan
failure
Morbid obesity, lymph leak
Thrombosis 192 Thrombolysis Death from intracranial
hemorrhage
Simultaneous femoropopliteal
bypass grafting at initial
operation; sequence of occlusions
not known
Thrombosis 10 Thrombectomy and
interposition graft to
common femoral artery
Graft patent at last follow-
up (19 mo after EVAR)
History of breast, ovarian, and
colon cancer, hypercoagulable
state
Anastomotic* disruption 1 Repair on postoperative
day 1
Death from graft infection,
postoperative day 36
Femoral endarterectomy
Anastomotic disruption 1 Repair with interposition
graft to superficial
femoral artery
Graft patent at last follow-
up (48 mo after EVAR)
Femoral endarterectomy
Pseudoaneurysm 48 Repair on postoperative
day 48
Graft patent at last follow-
up (4 mo after EVAR)
History of aneurysm
Pseudoaneurysm 205 Repair on postoperative
day 205, followed by
anticoagulation therapy
Death from intracranial
hemorrhage
EVAR, Endovascular aneurysm repair.
*Same patient.
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can Society of Anesthesiologists grade III disease or higher.
Preoperative assessment included catheter arteriography
and computed tomography (CT).
The study protocol was approved by the US Food and
Drug Administration and by the University of California
Institutional Review Board. Full informed consent was
obtained from all patients.
Operative technique. All procedures were performed
in the operating room with fluoroscopic guidance. All
patients received a single dose of intravenous antibiotic
before the incision was made. General anesthesia was used
in 24 patients (16%), and spinal or epidural anesthesia was
used in 124 patients (84%). In the first nine patients the
femoral arteries were exposed through standard longitudi-
nal groin incisions; in the rest, we made oblique incisions at
the level of the inguinal ligament. Technical details of
aortomonoiliac stent-graft technique and contralateral iliac
occlusion have been outlined.3,13,14 Expandable polytetra-
fluoroethylene (ePTFE) was used as CFBG conduit; all
grafts were 8 mm in diameter, and none were externally
supported. All were tunneled through the subcutaneous
fat. Heparin was given before catheter insertion, followed
by protamine at the conclusion of the operation.
Follow-up. Patients were evaluated with contrast
material–enhanced CT before discharge from the hospital.
Follow-up examination, plain abdominal radiography, and
repeat CT were performed at 1, 3, and 6 months, and
annually thereafter.
RESULTS
Mean operative time was 196.6  69 minutes, with
estimated mean blood loss 258  320 mL. Five patients
died within 30 days of operation, for a 30-day mortality rate
of 3.3% (Table II). Total morbidity rate, not involving
complications of CFBG, was 14% (20 patients), with mean
follow-up of 23.6  16.2 months (Table III).
Eight patients (5.4%) had nine CFBG-related compli-
cations, including disruption in 2 patients, infection in 3
patients, thrombosis in 2 patients, and pseudoaneurysm in
2 patients.
Four complications resulted in death. Two disruptions
involved a femoral anastomosis within 24 hours of initial
operation. Both patients had undergone femoral endarter-
ectomy at the original operation. One of these patients
returned 30 days later with graft infection. Reconstruction
was performed with greater saphenous vein, but the patient
died of necrotizing fasciitis of the wound and multiple
organ failure. A second patient with graft infection re-
turned 15 months after endovascular aneurysm repair, and
recovered after reconstruction with cryopreserved femoral
vein. The third patient had infection limited to the wound,
and underwent operative debridement and sartorious flap
reconstruction. The graft itself was uninvolved. Indeed,
the diagnosis of wound infection was somewhat ques-
tionable, because local signs consisted solely of fluid
drainage and wound necrosis, and systemic signs most
Fig 1. Life table analysis results for complications involving cross-femoral bypass graft after aortomonoiliac endovas-
cular repair.
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likely resulted from bronchopneumonia, from which the
patient died.
Graft thrombosis occurred in two patients. In one of
these patients, thrombectomy and interposition graft de-
veloped at 10 days. This patient survived for 3 years with
ovarian cancer before EVAR. Subsequent to EVAR, breast
and colon cancer were diagnosed. Contributory factors to
graft thrombosis included hypercoagulable state and dis-
section of the outflow common femoral artery, which was
replaced with a segment of ePTFE. The second patient with
graft thrombosis returned 6 months after EVAR. This
patient died as a result of intracranial hemorrhage while
undergoing an attempt at thrombolysis at another hospital.
At autopsy both the graft and its outflow, a femoropopliteal
bypass graft, were occluded.
In one patient a pseudoaneurysm developed at 7
months. Repair was performed, but the patient died of
intracranial hemorrhage during postoperative resumption
of long-term anticoagulation therapy. No autopsy was per-
formed. Another patient, with a history of multiple aneu-
rysms, returned 6 weeks postoperatively with a femoral
anastomotic pseudoaneurysm, which was successfully re-
paired surgically. These results are summarized in Table IV.
At life table analysis, freedom from CFBG complication
was 96.3%  1.6% at 12 months (112 patients), 94.1% 
2.2% at 24 months (63 patients), and 94.1%  2.2% at 48
months (18 patients; Fig 1). Overall survival in this patient
group at high risk was 83.4%  3.1% at 12 months, 70.4%
 4.1% at 24 months, 56.5%  5.3% at 36 months (31
patients), and 44.8% 6.4% at 48 months (14 patients; Fig
2).
DISCUSSION
Improvements in stent-graft design have enabled a
steady increase in the potential scope of EVAR. Nonethe-
less, it can be difficult to insert a bifurcated (aortobiiliac)
stent graft in the presence of severe iliac disease. Under
these circumstances an aortomonoiliac stent graft with
CFBG and contralateral iliac occlusion7 may be a better
option. An important concern when using this approach
has been the fate of the CFB graft.
Most reports of poor CFB graft patency and high
complication rate are based on patients with occlusive
artery disease.8 Better outflow and better patency rate are
found when the primary problem is arterial aneurysm.
In our series of 148 patients, the CFB graft was durable,
with a low complication rate (5.4%). But when complica-
tions did occur, the consequences were dire. Four of 8
patients with CFBG-related complications died.
Fig 2. Life table analysis for mortality after aortomonoiliac endovascular repair and cross-femoral bypass graft
reconstruction.
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In retrospect, many of these CFBG-related complica-
tions might have been prevented, inasmuch as they all had
identifiable cause. For example, all wound or graft infection
complicated femoral exposure through a longitudinal inci-
sion. Since changing to an oblique incision, we have per-
formed 139 repairs without a single wound or graft infec-
tion. Both anastomotic disruptions occurred after femoral
endarterectomy. Perhaps this complication could have
been prevented had we been able to avoid heavily calcified
plaques when puncturing the artery.
Femoral thrombosis, hypercoagulable state, and com-
promised arterial outflow were easy to identify, but were
less easy to prevent without excluding many patients from
EVAR.
Longer follow-up might have been expected in this
study, given the time that has elapsed since we performed
most of these repairs. The explanation lies in decreased
long-term survival in patients at high risk. Life table analysis
demonstrated that these patients were more likely to die of
comorbid conditions than they were to experience late
complications of CFBG.
In summary, CFBG-related mortality and morbidity
were low within the limited life expectancy of a high-risk
patient group . On the basis of these results, we believe that
need for CFBG should not discourage aortomonoiliac
EVAR when unfavorable iliac anatomy complicates inser-
tion of a bifurcated stent graft.
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